Peripheral Tissue Perfusion in Intensive Care
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Apr 24, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on understanding how certain treatments affect blood flow in the skin and other parts of the body in patients who are critically ill due to acute circulatory failure, which can happen in conditions like sepsis or heart failure. The researchers want to see how different medical interventions, such as giving fluids or medications that support blood pressure, influence the way blood moves through the body’s tissues.
To participate in this study, patients must be in the intensive care unit and facing acute circulatory failure related to their condition. However, patients who are very agitated, experiencing severe bleeding, or have serious skin issues won't be eligible. For those who do participate, the trial will monitor changes in blood flow after treatment, helping us learn more about how to improve care for critically ill patients in the future. Please note that this trial is not yet recruiting participants, so it will not begin for a while.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients in intensive care unit with acute circulatory failure related to sepsis or cardiac failure requiring therapeutic intervention
- Exclusion Criteria:
- • Agitation
- • Hemorrhagic shock
- • Severe skin lesions
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported